Potentiation of apoptosis by histone deacetylase inhibitors and doxorubicin combination: Cytoplasmic cathepsin B as a mediator of apoptosis in multiple myeloma

British Journal of Cancer

Volumn 104, Issue 6, 2011, Pages 957-967

  Cheriyath, V ^a   Kuhns, M A ^a   Kalaycio, M E ^a   Borden, E C ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

apoptosis and multiple myeloma; cathepsin B; doxorubicin; HDAC inhibitors

Indexed keywords

APOPTOSIS INDUCING FACTOR; BUTYRIC ACID; CASPASE 3; CASPASE 7; CATHEPSIN B; DOXORUBICIN; PROTEIN P53; VORINOSTAT;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL SURVIVAL; CELL VIABILITY; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CYTOPLASM; DRUG POTENTIATION; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; EX VIVO STUDY; HUMAN; HUMAN CELL; IC 50; MONOTHERAPY; MULTIPLE MYELOMA; MYELOMA CELL; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN TRANSPORT;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CASPASES; CATHEPSIN B; CELL LINE, TUMOR; CELL SURVIVAL; CYTOPLASM; DOXORUBICIN; DRUG EVALUATION, PRECLINICAL; DRUG SYNERGISM; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; MULTIPLE MYELOMA; RNA, SMALL INTERFERING;

EID: 79952697614     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2011.42     Document Type: Article

References (51)

1. Badros A, Burger AM, Philip S, Niesvizky R, Kolla SS, Goloubeva O, Harris C, Zwiebel J, Wright JJ, Espinoza-Delgado I, Baer MR, Holleran JL, Egorin MJ, Grant S (2009) Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma. Clin Cancer Res 15(16): 5250-5257
2. Bae SI, Cheriyath V, Jacobs BS, Reu FJ, Borden EC (2008) Reversal of methylation silencing of Apo2L/TRAIL receptor 1 (DR4) expression overcomes resistance of SK-MEL-3 and SK-MEL-28 melanoma cells to interferons (IFNs) or Apo2L/TRAIL. Oncogene 27(4): 490-498
3. Balliet RM, Chen G, Gallagher CJ, Dellinger RW, Sun D, Lazarus P (2009) Characterization of UGTs active against SAHA and association between SAHA glucuronidation activity phenotype with UGT genotype. Cancer Res 69(7): 2981-2989
4. Bergsagel PL, Kuehl WM (2001) Chromosome translocations in multiple myeloma. Oncogene 20(40): 5611-5622
5. Bidere N, Lorenzo HK, Carmona S, Laforge M, Harper F, Dumont C, Senik A (2003) Cathepsin D triggers Bax activation, resulting in selective apoptosis-inducing factor (AIF) relocation in T lymphocytes entering the early commitment phase to apoptosis. J Biol Chem 278(33): 31401-31411 (Pubitemid 36994661)
6. Biswas G, Guha M, Avadhani NG (2005) Mitochondria-to-nucleus stress signaling in mammalian cells: nature of nuclear gene targets, transcription regulation, and induced resistance to apoptosis. Gene 354: 132-139 (Pubitemid 41116692)
7. Boya P, Gonzalez-Polo RA, Poncet D, Andreau K, Vieira HL, Roumier T, Perfettini JL, Kroemer G (2003) Mitochondrial membrane permeabiliza-tion is a critical step of lysosome-initiated apoptosis induced by hydroxychloroquine. Oncogene 22(25): 3927-3936 (Pubitemid 36819666)
8. Broker LE, Huisman C, Span SW, Rodriguez JA, Kruyt FA, Giaccone G (2004) Cathepsin B mediates caspase-independent cell death induced by microtubule stabilizing agents in non-small cell lung cancer cells. Cancer Res 64(1): 27-30 (Pubitemid 38114077)
9. Campbell RA, Sanchez E, Steinberg J, Shalitin D, Li ZW, Chen H, Berenson JR (2010) Vorinostat enhances the antimyeloma effects of melphalan and bortezomib. Eur J Haematol 84(3): 201-211
10. Carew JS, Nawrocki ST, Kahue CN, Zhang H, Yang C, Chung L, Houghton JA, Huang P, Giles FJ, Cleveland JL (2007) Targeting autophagy augments the anticancer activity of the histone deacetylase inhibitor SAHA to overcome Bcr-Abl-mediated drug resistance. Blood 110(1): 313-322 (Pubitemid 47026849)
11. Catalano MG, Fortunati N, Pugliese M, Poli R, Bosco O, Mastrocola R, Aragno M, Boccuzzi G (2006) Valproic acid, a histone deacetylase inhibitor, enhances sensitivity to doxorubicin in anaplastic thyroid cancer cells. J Endocrinol 191(2): 465-472 (Pubitemid 44830622)
12. Chen CS, Wang YC, Yang HC, Huang PH, Kulp SK, Yang CC, Lu YS, Matsuyama S, Chen CY (2007) Histone deacetylase inhibitors sensitize prostate cancer cells to agents that produce DNA double-strand breaks by targeting Ku70 acetylation. Cancer Res 67(11): 5318-5327 (Pubitemid 46997271)
13. Cheriyath V, Glaser KB, Waring JF, Baz R, Hussein MA, Borden EC (2007a) G1P3, an IFN-induced survival factor, antagonizes TRAIL-induced apoptosis in human myeloma cells. J Clin Invest 117(10): 3107-3117 (Pubitemid 47529640)
14. Cheriyath V, Jacobs BS, Hussein MA (2007b) Proteasome inhibitors in the clinical setting: benefits and strategies to overcome multiple myeloma resistance to proteasome inhibitors. Drugs R D 8(1): 1-12 (Pubitemid 46191803)
15. Dai Y, Rahmani M, Dent P, Grant S (2005) Blockade of histone deacetylase inhibitor-induced RelA/p65 acetylation and NF-kappaB activation potentiates apoptosis in leukemia cells through a process mediated by oxidative damage, XIAP downregulation, and c-Jun N-terminal kinase 1 activation. Mol Cell Biol 25(13): 5429-5444 (Pubitemid 40853579)
16. Droga-Mazovec G, Bojic L, Petelin A, Ivanova S, Romih R, Repnik U, Salvesen GS, Stoka V, Turk V, Turk B (2008) Cysteine cathepsins trigger caspase-dependent cell death through cleavage of bid and antiapoptotic Bcl-2 homologues. J Biol Chem 283(27): 19140-19150
17. Egger G, Liang G, Aparicio A, Jones PA (2004) Epigenetics in human disease and prospects for epigenetic therapy. Nature 429(6990): 457-463 (Pubitemid 38715140)
18. Foghsgaard L, Lademann U, Wissing D, Poulsen B, Jaattela M (2002) Cathepsin B mediates tumor necrosis factor-induced arachidonic acid release in tumor cells. J Biol Chem 277(42): 39499-39506 (Pubitemid 35190927)
19. Glaser KB (2007) HDAC inhibitors: clinical update and mechanism-based potential. Biochem Pharmacol 74(5): 659-671 (Pubitemid 47096639)
20. Guo B, Zhai D, Cabezas E, Welsh K, Nouraini S, Satterthwait AC, Reed JC (2003) Humanin peptide suppresses apoptosis by interfering with Bax activation. Nature 423(6938): 456-461 (Pubitemid 36626999)
21. Hajji N, Wallenborg K, Vlachos P, Nyman U, Hermanson O, Joseph B (2008) Combinatorial action of the HDAC inhibitor trichostatin A and etoposide induces caspase-mediated AIF-dependent apoptotic cell death in non-small cell lung carcinoma cells. Oncogene 27(22): 3134-3144 (Pubitemid 351693171)
22. He J, Tohyama Y, Yamamoto K, Kobayashi M, Shi Y, Takano T, Noda C, Tohyama K, Yamamura H (2005a) Lysosome is a primary organelle in B cell receptor-mediated apoptosis: an indispensable role of Syk in lysosomal function. Genes Cells 10(1): 23-35 (Pubitemid 40352615)
23. Ivanova S, Repnik U, Bojic L, Petelin A, Turk V, Turk B (2008) Lysosomes in apoptosis. Methods Enzymol 442: 183-199
24. Laird PW (2005) Cancer epigenetics. Hum Mol Genet 14(Spec No 1): R65-R76 (Pubitemid 40542622)
25. Lincz LF, Yeh TX, Spencer A (2001) TRAIL-induced eradication of primary tumour cells from multiple myeloma patient bone marrows is not related to TRAIL receptor expression or prior chemotherapy. Leukemia 15(10): 1650-1657 (Pubitemid 32994686)
26. Ludwig H, Beksac M, Blade J, Boccadoro M, Cavenagh J, Cavo M, Dimopoulos M, Drach J, Einsele H, Facon T, Goldschmidt H, Harousseau JL, Hess U, Ketterer N, Kropff M, Mendeleeva L, Morgan G, Palumbo A, Plesner T, San Miguel J, Shpilberg O, Sondergeld P, Sonneveld P, Zweegman S (2010) Current multiple myeloma treatment strategies with novel agents: a European perspective. Oncologist 15(1): 6-25
27. Luszczek W, Cheriyath V, Mekhail TM, Borden EC (2010) Combinations of DNA methyltransferase and histone deacetylase inhibitors induce DNA damage in small cell lung cancer cells: correlation of resistance with IFN-stimulated gene expression. Mol Cancer Ther 9(8): 2309-2321
28. Mandic A, Viktorsson K, Strandberg L, Heiden T, Hansson J, Linder S, Shoshan MC (2002) Calpain-mediated Bid cleavage and calpain-independent Bak modulation: two separate pathways in cisplatin-induced apoptosis. Mol Cell Biol 22(9): 3003-3013 (Pubitemid 34437459)
29. Marchion DC, Bicaku E, Daud AI, Richon V, Sullivan DM, Munster PN (2004) Sequence-specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acid. J Cell Biochem 92(2): 223-237
30. Marks PA, Xu WS (2009) Histone deacetylase inhibitors: potential in cancer therapy. J Cell Biochem 107(4): 600-608
31. Mazumder S, Plesca D, Kinter M, Almasan A (2007) Interaction of a cyclin E fragment with Ku70 regulates Bax-mediated apoptosis. Mol Cell Biol 27(9): 3511-3520 (Pubitemid 46685225)
32. Mitsiades CS, Hayden PJ, Anderson KC, Richardson PG (2007) From the bench to the bedside: emerging new treatments in multiple myeloma. Best Pract Res Clin Haematol 20(4): 797-816 (Pubitemid 350215385)
33. Mitsiades CS, Mitsiades NS, McMullan CJ, Poulaki V, Shringarpure R, Hideshima T, Akiyama M, Chauhan D, Munshi N, Gu X, Bailey C, Joseph M, Libermann TA, Richon VM, Marks PA, Anderson KC (2004) Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. Proc Natl Acad Sci USA 101(2): 540-545 (Pubitemid 38084672)
34. Mitsiades N, Mitsiades CS, Richardson PG, McMullan C, Poulaki V, Fanourakis G, Schlossman R, Chauhan D, Munshi NC, Hideshima T, Richon VM, Marks PA, Anderson KC (2003) Molecular sequelae of histone deacetylase inhibition in human malignant B cells. Blood 101(10): 4055-4062 (Pubitemid 36857886)
35. Moradei O, Vaisburg A, Martell RE (2008) Histone deacetylase inhibitors in cancer therapy: new compounds and clinical update of benzamide-type agents. Curr Top Med Chem 8(10): 841-858 (Pubitemid 351984708)
36. Niesvizky R, Badros A (2010) Complications of multiple myeloma therapy, part2: risk reduction and management of venus thromboembolism, osteonecrosis of the jaw, renal complications, and anemia. J Natl Compr Canc Netw 8(Suppl 1): S13-S20
37. Ostenfeld MS, Fehrenbacher N, Hoyer-Hansen M, Thomsen C, Farkas T, Jaattela M (2005) Effective tumor cell death by sigma-2 receptor ligand siramesine involves lysosomal leakage and oxidative stress. Cancer Res 65(19): 8975-8983 (Pubitemid 41377389)
38. Pan L, Lu J, Wang X, Han L, Zhang Y, Han S, Huang B (2007) Histone deacetylase inhibitor trichostatin a potentiates doxorubicin-induced apoptosis by up-regulating PTEN expression. Cancer 109(8): 1676-1688 (Pubitemid 46595705)
39. Paquet C, Sane AT, Beauchemin M, Bertrand R (2005) Caspase- and mitochondrial dysfunction-dependent mechanisms of lysosomal leakage and cathepsin B activation in DNA damage-induced apoptosis. Leukemia 19(5): 784-791 (Pubitemid 40663098)
40. Pei XY, Dai Y, Grant S (2004) Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors. Clin Cancer Res 10(11): 3839-3852 (Pubitemid 38697620)
41. Richards T, Weber D (2010) Advances in treatment for relapses and refractory multiple myeloma. Med Oncol 27(Suppl 1): S25-S42
42. Richardson P, Mitsiades C, Colson K, Reilly E, McBride L, Chiao J, Sun L, Ricker J, Rizvi S, Oerth C, Atkins B, Fearen I, Anderson K, Siegel D (2008) Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma. Leuk Lymphoma 49(3): 502-507 (Pubitemid 351298334)
43. Richardson PG, Mitsiades C, Schlossman R, Munshi N, Anderson K (2007) New drugs for myeloma. Oncologist 12(6): 664-689 (Pubitemid 47036203)
44. Richon VM, Garcia-Vargas J, Hardwick JS (2009) Development of vorinostat: current applications and future perspectives for cancer therapy. Cancer Lett 280(2): 201-210
45. Sanchez E, Shen J, Steinberg J, Li M, Wang C, Bonavida B, Chen H, Li ZW,Berenson JR (2010) The histone deacetylase inhibitor LBH589 enhances the anti-myeloma effects of chemotherapy in vitro and in vivo. Leuk Res; e-pub ahead of print 2010
46. Sanchez-Gonzalez B, Yang H, Bueso-Ramos C, Hoshino K, Quintas-Cardama A, Richon VM, Garcia-Manero G (2006) Antileukemia activity of the combination of an anthracycline with a histone deacetylase inhibitor. Blood 108(4): 1174-1182 (Pubitemid 44232012)
47. Sandes E, Lodillinsky C, Cwirenbaum R, Arguelles C, Casabe A, Eijan AM (2007) Cathepsin B is involved in the apoptosis intrinsic pathway induced by Bacillus Calmette-Guerin in transitional cancer cell lines. Int J Mol Med 20(6): 823-828
48. Shoshan-Barmatz V, Keinan N, Zaid H (2008) Uncovering the role of VDAC in the regulation of cell life and death. J Bioenerg Biomembr 40(3): 183-191
49. Turk B, Stoka V (2007) Protease signalling in cell death: caspases versus cysteine cathepsins. FEBS Lett 581(15): 2761-2767 (Pubitemid 46874395)
50. Wang C, Jiang Z, Yao J, Wu X, Sun L, Liu C, Duan W, Yan M, Liu J, Zhang L (2008) Participation of cathepsin B in emodin-induced apoptosis in HK-2 Cells. Toxicol Lett 181(3): 196-204
51. Zhang H, Kim JK, Edwards CA, Xu Z, Taichman R, Wang CY (2005) Clusterin inhibits apoptosis by interacting with activated Bax. Nat Cell Biol 7(9): 909-915 (Pubitemid 41486292)